Skip to main content

Advertisement

Table 6 Patients with moderate to very severe nausea/vomiting or diarrhoea by demographic, treatment and clinical variables.

From: Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

Variable Category Nausea/vomiting p Diarrhoea p
B symptoms No 43/285 (15.1) 0.048 34/284 (12.0) 0.003
  Yes 69/324 (21.3)   68/326 (20.9)  
Sex Female 68/285 (23.9) 0.001 54/286 (18.9) 0.179
  Male 44/324 (13.6)   48/324 (14.8)  
Age < 75 years 84/453 (18.5) 0.869 65/452 (14.4) 0.009
  GE 75 years 28/156 (17.9)   37/158 (23.4)  
Chemotherapy CHOP 72/315 (22.9) 0.003 58/313 (18.5) 0.219
  PMitCEBO 40/294 (13.6)   44/297 (14.8)  
Stage Stage 0–2 40/227 (17.6) 0.705 30/225 (13.3) 0.086
  Stage 3–4 72/382 (18.8)   72/385 (18.7)  
Performance status Level 0–1 60/430 (14.0) < 0.001 50/429 (11.7) < 0.001
  Level 2–4 48/169 (28.4)   50/171 (29.2)  
  1. Number (per cent).